# Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

> **NCT01134341** · PHASE1 · COMPLETED · sponsor: **Acrotech Biopharma Inc.** · enrollment: 34 (actual)

## Conditions studied

- Cutaneous T-cell Lymphoma
- Mycosis Fungoides
- Sezary Syndrome
- Primary Cutaneous Anaplastic Large Cell Lymphoma

## Interventions

- **DRUG:** Pralatrexate Injection
- **DRUG:** Bexarotene Capsules
- **DIETARY_SUPPLEMENT:** Vitamin B12
- **DIETARY_SUPPLEMENT:** Folic Acid

## Key facts

- **NCT ID:** NCT01134341
- **Lead sponsor:** Acrotech Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2019-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01134341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01134341, "Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01134341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*